Effects of Single Nucleotide Polymorphisms in the Human \u3ci\u3eHolocarboxylase Synthetase\u3c/i\u3e Gene on Catalytic Activity by Esaki, Shingo
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Nutrition & Health Sciences Dissertations & 
Theses Nutrition and Health Sciences, Department of 
8-2011 
Effects of Single Nucleotide Polymorphisms in the Human 
Holocarboxylase Synthetase Gene on Catalytic Activity 
Shingo Esaki 
University of Nebraska-Lincoln, shingoe@huskers.unl.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/nutritiondiss 
 Part of the Dietetics and Clinical Nutrition Commons, and the Molecular, Genetic, and Biochemical 
Nutrition Commons 
Esaki, Shingo, "Effects of Single Nucleotide Polymorphisms in the Human Holocarboxylase Synthetase 
Gene on Catalytic Activity" (2011). Nutrition & Health Sciences Dissertations & Theses. 26. 
https://digitalcommons.unl.edu/nutritiondiss/26 
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition & Health Sciences 
Dissertations & Theses by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
 
 
EFFECTS OF SINGLE NUCLEOTIDE 
POLYMORPHISMS IN THE HUMAN 
HOLOCARBOXYLASE SYNTHETASE GENE ON 
CATALYTIC ACTIVITY 
 
 
By 
 
 
 
Shingo Esaki 
 
 
 
A THESIS 
 
 
 
Presented to the Faculty of  
The Graduate College at the University of Nebraska  
In Partial Fulfillment of the Requirements  
For the Degree of Master of Science 
 
 
Major: Nutrition 
 
 
Under supervision of Professor Janos Zempleni 
 
 
Lincoln, Nebraska 
 
 
August, 2011 
 
 
EFFECTS OF SINGLE NUCLEOTIDE 
POLYMORPHISMS IN THE HUMAN 
HOLOCARBOXYLASE SYNTHETASE GENE ON 
CATALYTIC ACTIVITY 
 
Shingo Esaki, M.S 
University of Nebraska, 2011 
 
Advisor: Janos Zempleni 
 
Holocarboxylase synthetase (HCS) catalyzes the covalent binding of biotin to 
carboxylases and histones in eukaryotic cells. Biotinylated carboxylases play essential 
roles in the metabolism of fatty acids, amino acids, and glucose; biotinylated histones 
play essential roles in gene regulation and genome stability. HCS null individuals are not 
viable whereas HCS deficiency is linked to developmental delays and phenotypes such as 
short life span and low stress resistance.  Greater than 2,500 single nucleotide 
polymorphisms (SNPs) have been reported for HCS, but the biological importance of 
these polymorphisms is unknown. We hypothesized that some of these SNPs impair 
catalytic activity and that this effect can be overcome by dietary intervention with biotin. 
Here, we analyzed the enzyme kinetics of five recombinant HCS variants using a 
propionyl-CoA carboxylase surrogate (“p67”) as substrate for biotinylation.  Vmax of 
variants L216R, V96F and G510R were 6%, 78% and 73%, respectively, of the Vmax in 
wild-type HCS.  The Km values of the variants V96F and G510R were not significantly 
different from wild-type HCS.  The activity of L216R was too low to allow for 
 
 
meaningful analysis of Km.  In contrast, the affinity of variant Q699R for biotin was 
significantly lower than that of wild type HCS (Km: 1.57 times that of wild type) and its 
Vmax could be restored to that of wild-type HCS by biotin supplementation.  This is the 
first biochemical characterization of catalytic activities of HCS variants.  Also, this is the 
first report to show that HCS activity can be restored to normal by biotin supplementation. 
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INTRODUCTION  
Biotin is a water-soluble vitamin involved in many metabolic pathways in 
mammals [Camporeale and Zempleni 2006].  It plays important roles in the metabolism 
of glucose, amino acids and fatty acids due to its role as a coenzyme in the metabolism of 
acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2), 3-methylcrotonyl-CoA carboxylase 
(MCC), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC) [Camporeale and 
Zempleni 2006; Chew, Sarath et al. 2007].  Biotin is also attached covalently to at least 
11 distinct lysine residues in histones H2A, H3 and H4 [Camporeale, Shubert et al. 2004; 
Kobza, Camporeale et al. 2005; Chew, Camporeale et al. 2006].  Biotinylation of histones 
participates in the cross-talk among various histone modifications and in gene regulation 
[Camporeale, Giordano et al. 2006; Chew, Raza et al. 2006; Camporeale, Zempleni et al. 
2007; Gralla, Camporeale et al. 2008].  
 Holocarboxylase synthetase (HCS, EC 6.3.4.10) is an enzyme that catalyzes 
biotinylation of the five human biotin-dependent carboxylases mentioned above (ACC1, 
ACC2, MCC, PC, and PCC).  The following four domains have been identified and 
characterized in human HCS: N-terminal domain, central domain, linker domain, and C-
terminal domain [Hassan, Moriyama et al. 2009].  Both N- and C-termini of HCS 
participate in substrate recognition [Hassan, Moriyama et al. 2009].  The central domain 
in HCS contains binding sites for both ATP and biotin [Leon-Del-Rio and Gravel 1994; 
1999; Kothapalli, Sarath et al. 2005].  The linker domain might play a role in conferring 
the flexibility needed for HCS to interact with a diverse group of substrates for 
biotinylation [Hassan, Moriyama et al. 2009]. 
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A series of mutations have been identified in the HCS gene; these mutations 
decrease HCS activity substantially and cause features such as exfoliative dermatitis, 
hypoglycemia, ketoacidosis, and reduced histone biotinylation.  While the prevalence of 
HCS mutations is low in the general population, early diagnosis is critical for a good 
prognosis.  Mutations that decrease the affinity of HCS for biotin are particularly 
responsive to treatment with pharmacological doses of biotin.  In addition, greater than 
2,500 SNPs have been reported for HCS in public databases. The biological importance 
of these polymorphisms is unknown.  
This thesis has the following two major goals.  (1) To identify HCS SNPs that 
affect the catalytic activity of HCS.  This aim tests the hypothesis that some, but not all, 
SNPs in human HCS decrease enzyme activity.  Previous studies revealed that domains 
in the N-terminus, ATP-/biotin-binding site (central domain), and C-terminus are 
important for HCS activity [Hassan, Moriyama et al. 2009].   From each of these three 
domains, one to two known SNPs were selected that were likely to affect catalytic 
activity.  Candidate SNPs were those suspected to cause HCS conformational changes, 
e.g., substitution of hydrophobic for basic amino acids.  (2) To determine if higher 
concentration of biotin could restore substrate biotinylation by HCS variants to the levels 
of wild-type HCS.  This aim tests the hypothesis that supplementation with biotin 
increases the catalytic activity of HCS variants to levels seen with wild-type HCS.  These 
supplementation studies lay the groundwork for future dietary intervention studies.   
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LITERATURE REVIEW 
 
I. Biotin 
 
Biotin, also known as vitamin B7 or H, is an essential water-soluble vitamin 
involved in many metabolic pathways in mammals [Zempleni 2005].  Chemically, biotin 
is a monocarboxylic acid consisting of a ureido group, thiophane heterocyclic ring, and a 
valeric acid side chain [Zempleni 2001; Zempleni 2005; Hassan and Zempleni 2006] (Fig. 
1). 
 
         
 
Figure 1. Biotin structure 
 
Biotin is a coenzyme in carboxyl transfer reactions from microbes to animals 
and plants.  Biotin was first discovered by Kögl and Tönnis in 1934 while studying the 
growth requirements of yeast in synthetic media [Kogl and Tonnis 1932].  Mammals are 
auxotrophic for biotin and obtain it through dietary sources and from intestinal bacteria 
that can produce biotin de novo [Wakil, Stoops et al. 1983], or endogenously recover it 
4 
 
from pre-existing carboxylases.  Biotin can be found in high concentration in egg yolk, 
cow milk, liver and some vegetables [Said 2009].  For absorption of dietary biotin, the 
protein-bound biotin in foods has to be converted to free biotin by the action of 
gastrointestinal proteases, peptidases, and biotinidase [Zempleni 2005; Said 2009].  The 
adequate intake (AI) of biotin for adults is 30 µg /day.   
The following four proteins play major roles in the homeostasis of biotin in 
humans (Fig. 2): the sodium-dependent multi-vitamin transporter (SMVT), 
monocarboxylate transporter 1 (MCT1), biotinidase (BTD) and holocarboxylase 
synthetase (HCS).  In most mammalian tissues the primary transport protein of biotin is 
SMVT, which also transports pantothenic acid and lipoate [Wang, Huang et al. 1999; 
Said 2009].  MCT1 has been reported to participate in the transport of biotin, but its 
function is restricted to lymphoid cells [Zempleni and Mock 1999; Daberkow, White et 
al. 2003].  In mammals, biotin reutilization occurs through the action of BTD, a specific 
amidolyase which hydrolyzes biotin from biotinyl-lysine (biocytin) or short peptides 
containing biotin which are the products of normal proteolytic digestion of 
holocarboxylases [Wolf, Grier et al. 1985].  BTD is also required for the release of 
dietary protein-bound biotin. 
Within the cell, the most extensively characterised and understood function for 
biotin is to serve as a cofactor for biotin-dependent carboxylases (propionyl-CoA 
carboxylase (PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial 
acetyl-CoA carboxylase 2 (ACC2), pyruvate carboxylase (PC) and 3-methylcrotonyl- 
CoA carboxylase (MCC)) where it is required for the transfer of carbon dioxide from 
bicarbonate to organic acid metabolites and plays important roles in the metabolism 
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Figure 2. Biotin transport and metabolism. B: biotin, SMVT: sodium multivitamin 
transporter, MCT1: monocarboxylate transporter 1, HCS: holocarboxylase synthetase, 
PCC: propionyl-CoA carboxylase, ACC1: cytoplasmatic acetyl-CoA carboxylase α, 
ACC2: mitochondrial acetyl-CoA carboxylase β, PC: pyruvate carboxylase, MCC: and 3-
methylcrotonyl-CoA carboxylase [Figure source: Zempleni, Gralla et al. 2009]. 
 
 
of glucose, amino acids and fatty acids [Wood and Barden 1977; Samols, Thornton et al. 
1988; Knowles 1989; Attwood and Wallace 2002].  Biotin is covalently attached to this 
family of enzymes by biotin protein ligase (BPL).  Biotin-dependent carboxylases have 
half-lives of 1–8 days [Majerus and Kilburn 1969; Nakanishi and Numa 1970; Weinberg 
and Utter 1979; Weinberg and Utter 1980; Freytag and Utter 1983].  Both ACC1 and 
ACC2 catalyze the incorporation of bicarbonate into malonyl-CoA, a key regulatory step 
in fatty acid synthesis (ACC1) and mitochondrial fatty acid transport (ACC2).  MCC is 
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involved in the catabolism of the branched-chain amino acid leucine.  PC catalyzes the 
carboxylation of pyruvate to produce oxaloacetate in gluconeogenesis.  PCC is involved 
in the conversion of propionyl-CoA to methylmalonyl-CoA in the metabolism of odd-
chain fatty acids.  
 
II. Holocarboxylase Synthetase (HCS or HLCS) 
 
The Role of HCS in Humans 
 HCS is a biotin protein ligase (BPL): an enzyme that catalyzes biotin attachment 
onto the biotin-dependent enzymes - carboxylases and histones – in mammalian cells 
[Leon-Del-Rio and Gravel 1994; Narang, Dumas et al. 2004].  HCS catalyzes the 
biotinylation of the five mammalian biotin-dependent carboxylases mentioned above 
(ACC1, ACC2, MCC, PC, and PCC).  The covalent bond between the lysine residue of 
the carboxylases and biotin occurs in a two-step ATP-dependent reaction [Dakshinamurti 
and Chauhan 1994]. In the first step, biotinyl 5’-AMP (B-AMP) is generated; in the 
second step, biotin is transferred from B-AMP to the lysine residue in the 
apocarboxylases [Narang, Dumas et al. 2004] (Fig. 3). 
In addition, in response to changes in biotin availability, HCS has been 
demonstrated to function in regulating transcription of the gene that encodes HCS itself 
as well as those that code for propionyl-CoA carboxylase, pyruvate carboxylase, acetyl-
CoA carboxylase 1, and the sodium-dependent multivitamin transporter [Dakshinamurti 
and Cheah-Tan 1968; Chauhan and Dakshinamurti 1991].  This transcriptional regulatory 
process is associated with the soluble guanylyl cyclase signal transduction pathway 
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[Solorzano-Vargas, Pacheco-Alvarez et al. 2002].  It has also been suggested that HCS 
exerts its transcriptional regulatory role by catalyzing biotin linkage to histones 
[Zempleni 2005] (Fig. 4).  
 
 
Figure 3. Biotin metabolism in Homo sapiens.  Btd: biotinidase; HLCS: 
holocarboxylase synthetase; apocarboxylase: unbiotinylated carboxylase; 
holocarboxylase: biotinylated carboxylase (Figure source: QIAGEN; Valencia, CA) 
 
The carboxylases mentioned above are essential for cellular biosynthesis.  
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Therefore, defects in HCS, which reduce the biotin-dependent enzyme activity, affect 
several important metabolic processes, including fatty acid synthesis, gluconeogenesis, 
and amino acid catabolism. 
 
                           
 
Figure 4. HCS function in metabolism and transcription regulation.  The enzyme 
utilizes substrates biotin and ATP to catalyze synthesis of bio- 5′-AMP.  The HCS 
·intermediate complex interacts with carboxylases to transfer biotin or functions in 
transcription, perhaps through histone biotinylation [Figure Source: Ingaramo and 
Beckett 2009]. 
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HCS Structure and Domains 
Holocarboxylase synthetase (HCS or HCS, EC 6.34.10) is encoded by an 14-exon 
gene, HCS, located on chromosome 21q22.1 [Suzuki, Aoki et al. 1994]. The open 
reading frame of full-length HCS encodes 726 amino acids (2181bp) [Suzuki, Aoki et al. 
1994].  The existence of at least three splicing variants (76, 82, and 86 kDa) has been 
confirmed [Hiratsuka, Sakamoto et al. 1998]. HCS has been detected in cytoplasm, 
mitochondria, cell nuclei, and the nuclear lamina [Hiratsuka, Sakamoto et al. 1998; 
Narang, Dumas et al. 2004]. 
The following four domains have been identified and characterized in human 
HCS: N-terminal domain, central domain, linker domain, and C-terminal domain [Hassan, 
Moriyama et al. 2009] (Fig. 5).  Both N- and C-termini of HCS participate in substrate 
recognition [Hassan, Moriyama et al. 2009].  The central domain in HCS contains 
binding sites for both ATP and biotin [Leon-Del-Rio and Gravel 1994; Chapman-Smith 
and Cronan 1999; Kothapalli, Sarath et al. 2005].  The linker domain might play a role in 
conferring the flexibility needed for HCS to interact with a diverse group of substrates for 
biotinylation [Hassan, Moriyama et al. 2009]. 
The protein HCS has a homologous region (aa 448-701) to BirA, the biotin apo-
carboxyl carrier protein ligase of Escherichia coli [Suzuki, Aoki et al. 1994].  BirA ligase 
participates in the biotinylation of biotinoyl carboxyl carrier protein (BCCP) and its 
amino acid sequence is 21% identical with HCS [Chauhan and Dakshinamurti 1986; 
Bankson, Martin et al. 1987; Hymes and Wolf 1999; Hymes, Stanley et al. 2001]. 
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Figure 5. Four domains in human HCS: N-terminal domain (M1-F446); central domain 
“CD” (F471-S575) containing biotin transfer and ATP-binding sites; linker domain “L” 
(T610-V668); and C-terminal domain “CT” (H669-R718). The domains are drawn to scale 
[Figure source: Hassan, Moriyama et al. 2009]. 
 
HCS Deficiency 
Multiple carboxylase deficiency (MCD) is a rare autosomal recessive metabolic 
disease caused by defects of enzymes, either biotinidase (biotinidase deficiency, OMIM 
#253260) or holocarboxylase synthetase (HCS deficiency, OMIM 253270), in the biotin 
cycle [Sherwood, Saunders et al. 1982; Sweetman, Burri et al. 1985].    Patients with 
MCD present in the neonatal period or early infancy with metabolic acidosis, 
hyperammonemia, tachypnea, skin rash, feeding problems, hypotonia, seizures, 
developmental delay, alopecia, and coma [Tammachote, Janklat et al. 2010].  Diagnosis 
is suggested by urine organic acids analysis and confirmed by holocarboxylase synthetase 
enzyme assay or DNA mutation analysis [Tammachote, Janklat et al. 2010].  As little as 
10 milligrams per day of oral biotin usually improve clinical symptoms [Suormala, 
Fowler et al. 1997; Wolf 2001].  Patients with HCS deficiency usually have the neonatal 
or early-onset form, which may be fatal even within hours of birth [Sweetman, Nyhan et 
al. 1982], while patients with biotinidase deficiency have the juvenile or lateonset form.  
However, the age of onset and phenotypes are highly variable.  Reliable diagnosis of 
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either MCD types therefore requires enzyme activity or genetic analysis [Tammachote, 
Janklat et al. 2010]. 
 
Mutations and SNPs in HCS 
A series of mutations have been identified in the HCS gene [Dupuis, Leon-Del-
Rio et al. 1996; Yang, Aoki et al. 2001; Suzuki, Yang et al. 2005]; these mutations 
decrease HCS activity substantially and cause features such as exfoliative dermatitis, 
hypoglycemia, ketoacidosis, and reduced histone biotinylation [Balnave 1977; Wolf, 
Heard et al. 1985; Baumgartner and Suormala 1999; Kobza, Camporeale et al. 2005; 
Atamna, Newberry et al. 2007].  While the prevalence of HCS mutations is low in the 
general population [Suzuki, Yang et al. 2005], early diagnosis is critical for a good 
prognosis.  Mutations that decrease the affinity of HCS for biotin are particularly 
responsive to treatment with pharmacological doses of biotin [Suzuki, Yang et al. 2005].  
To date, there are at least 24 mutations reported in HCS (http://www.hgmd.cf.ac.uk, 
accessed June 2011). 
In addition, greater than 2,500 SNPs have been reported for HCS in public 
databases (http://www.genecards.org/cgibin/carddisp.pl?gene=HLCS&snp=2572&rf=/ 
home/genecards/current/website/carddisp.pl#snp, accessed May 2011).  The biological 
importance of these polymorphisms is unknown. 
 
HCS Catalytic Activity Assay in vitro 
Bioactivity of HCS has been probed in vitro using p67, a propionyl CoA 
carboxylase (PCC)-based polypeptide and a well-established HCS substrate [Lamhonwah, 
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Quan et al. 1987; Leon-Del-Rio and Gravel 1994; Campeau and Gravel 2001] which 
comprises the 67 C-terminal amino acids in human PCC and contains the consensus 
MKM motif for biotin bimding [Lamhonwah, Quan et al. 1987; Campeau and Gravel 
2001]. 
 
The Km Mutant Theory of HCS 
Burri et al. characterized HCS activity in cultured cells from seven patients with 
considerable differences in disease severity [Burri, Sweetman et al. 1985].  They showed 
that the Vmax values of patients' HCS were lower than the normal mean and were similar 
in all except one patient, and that the Km values for biotin were elevated to various 
degrees.  From their clinical and kinetic observations, they concluded that onset of the 
disease and its responsiveness to biotin administration is governed by the degree of 
abnormality in the Km of HCS.  Suormala et al. investigated the effects of biotin 
concentration on carboxylase activities in fibroblasts in five HCS-deficient patients 
[Suormala, Fowler et al. 1997].  The carboxylase activities of all patients normalized 
when the biotin concentration was increased to 10,000 nM.  In carboxylase reactivation 
studies, although the kinetics of PCC activation varied greatly, all cells restored their 
PCC activity to the normal or nearly normal level (>87%).  Reactivation of PCC activity 
in relation to time and biotin concentration correlated well with the severity and age at 
onset of the illness in four patients.  These results were consistent with the original Km 
mutant theory proposed by Burri et al. [Burri, Sweetman et al. 1985]. 
An expression study demonstrated that the Km of the Val550Met HCS mutant was 
higher than, but the Km of the Leu237Pro-mutant was the same as, that of the wild-type 
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enzyme [Aoki, Suzuki et al. 1997].  Thus, Sakamoto et al. questioned whether the Km 
mutant theory could be applied to all patients with HCS deficiency, and proposed that not 
only the Km of HCS for biotin, but also the Vmax was an important factor in determining 
the severity of symptoms and their responsiveness to biotin therapy [Aoki, Suzuki et al. 
1997]. 
The Km values for biotin of the Gly581Ser and delThr610 mutant proteins were 
45 and 3 times higher, respectively, than the wild-type value [Sakamoto, Suzuki et al. 
1999].  Previous studies [Aoki, Suzuki et al. 1997] suggested that mutations within the 
homologous region (aa 448-701) to BirA result in elevated Km values (Km mutants).  The 
mutations Arg183Pro, Leu216Arg, Leu237Pro, Val333Glu, and Val363Asp were located 
outside the homologous region (non- Km mutants).  The Km values of these mutants 
differed only slightly from that of the wild type, whereas the Vmax values were extremely 
lower than that of the wild type [Sakamoto, Suzuki et al. 1999].  The result suggested that 
non- Km mutants can be a cause of biotin responsive HCS deficiency, thereby their 
hypothesis was confirmed [Aoki, Suzuki et al. 1997]. 
 
Vmax Mutants of HCS 
The Vmax mutants group of mutations, namely Arg183Pro, Leu216Arg and 
Leu237Pro, map outside of the conserved catalytic core of HCS to the N-terminal region.  
Patients with these mutant HCS alleles vary in their responsiveness to biotin treatment.  
Although the N-terminal region has been implicated in catalysis [Campeau and Gravel 
2001], the precise role played by this extension is poorly understood.  These mutations 
have provided an insight into the structure and function relationships of HCS.  
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Interestingly, alignment of the BPL sequences from human, dog, horse, mouse, rat, 
chicken, Danio and Fugu show that the N-terminal extension is conserved amongst these 
vertebrate species.  Furthermore, the equivalent amino acids at the above positions are 
invariant between these species, again highlighting their importance [Pendini, Bailey et al. 
2008]. 
 
The Importance of HCS N-terminal Domain for its Catalytic Activity 
The importance of the domain of HCS outside the homologous region (aa 448-
701) to BirA for enzymatic activity was examined in the expression study with HCS 
deletion mutants by Hiratsuka et al. [Hiratsuka, Sakamoto et al. 1998].  The N-terminal 
amino acid region up to Ile117 had a much less effect on the activity than the amino acid 
sequence starting between Ile117 and Met234. 
 
The Physiologic Biotin Concentration and HCS Catalytic Activity 
The physiologic biotin concentration of human serum was estimated to be 1-3 nM 
and that of liver 0.5-4 nM [Baker 1985].  More recently, the serum biotin level was 
estimated to be about 0.24 nM [Mock, Lankford et al. 1995].  These concentrations are 
lower than the Km values of wild-type HCS that were measured in cultured fibroblasts 
[Burri, Sweetman et al. 1985; Suzuki, Aoki et al. 1996] or lymphoblasts [Burri, 
Sweetman et al. 1985], using CCP or PCC as a substrate.  Therefore, the mutant HCS 
proteins harboring the Leu216Arg, Arg183Pro, Leu237Pro, Val333Glu, or Val363Asp 
would not show full activity in the physiologic state.  Biotin treatment increases the 
biotin concentration in serum up to several hundred nanomolars [Burri, Sweetman et al. 
15 
 
1985; Suormala, Fowler et al. 1997], thereby helping to increase the velocity of 
biotinylation in the cells. 
 
The Difference in the Mechanism of Biotin Attachment to Carboxylases and 
Histones 
HCS was found to be a constituent of nuclei, in addition to the cytoplasm of cells, 
suggesting that HCS could be responsible for biotinylating histones in vivo [Cronan 
2001].  However, as histones do not contain the biotin binding motif as seen in 
carboxylases, the mechanism and specificity of biotin attachment to histones might be 
expected to be significantly different [Healy, McDonald et al.].  
 
III. Biotinidase (BTD) 
 
Biotinidase belongs to the nitrilase superfamily of enzymes, which consists of 12 
families of amidases, N-acyltransferases and nitrilases [Brenner 2002].  Some members 
of the nitrilase superfamily (vanins-1, -2 and -3) share significant sequence similarities 
with BTD [Maras, Barra et al. 1999].  Human BTD gene localizes to chromosome 3p25 
and its structure has been determined [Cole Knight, Reynolds et al. 1998]. The human 
BTD gene contains four exons: A125-44, B45-309, C310-459 and D460-1961, and they span at 
least 44 kb and encode a protein of 543 amino acids [Stanley, Hymes et al. 2004]. The 
mature enzyme is encoded by exons B through D. The coding region of BTD has two in-
frame start codons, both of which might initiate translation [Stanley, Hymes et al. 2004]. 
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The cellular distribution of BTD is controversial. While the existence of BTD 
acitivty in microsomes and mitochondria is accepted universally [Pispa 1965; Garganta 
and Wolf 1990; Nilsson and Ronge 1992], the presence of BTD in nuclei is less certain 
[Zempleni, Hassan et al. 2008]. 
The classical role of BTD in metabolism is to hydrolyze biocytin (biotinyl- ε -
lysine) generated in the breakdown of biotin-dependent carboxylases [Hymes, 
Fleischhauer et al. 1995].  Thus, free biotin is released and recycled in holocarboxylase 
synthesis and used in other processes [Camporeale and Zempleni 2006].  The role of 
BDT in biotinylation of histones has been demonstrated based on in vitro studies with 
purified histones [Hymes, Fleischhauer et al. 1995].  It was proposed that BTD might 
mediate the binding of biotin to histones by the hydrolysis of biocytin forming a biotinyl-
thioester intermediate (cysteine-bound biotin) near its active site. Thus, biotin is bound to 
the biotinyl moiety from the cysteine residue and transfer to the ε-amino group of the 
lysine in histones [Hymes, Fleischhauer et al. 1995; Hymes and Wolf 1999].  The Km 
value for hydrolysis of biocytin by biotinidase is in the micromolar range and hydrolysis 
occurs optimally at pH 5.5–6, with a precipitous decrease in activity above pH 7.  On the 
other hand, biotinylation of histones by biotinidase occurs at physiological pH and 
concentrations of biocytin (nanomolar range) [Hymes, Fleischhauer et al. 1995]. 
Evidence has been provided that BTD might catalyze debiotinylation of histones 
[Ballard, Wolff et al. 2002].  It was proposed that variables such as microenviroment in 
chromatin, posttranscriptional modifications and alternative splicing might determine 
whether BTD acts as a biotinyl histone transferase or histone debiotinylase [Zempleni 
2005].  For example covalent modifications such as glycosylation might influence the 
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enzyme activity to biotinylate or debiotinylate histones [Cole, Reynolds et al. 1994; 
Ballard, Wolff et al. 2002].  In the same way, the presence of cofactors such as high 
concentrations of biocytin might favor and increase the rate of biotinylation of histones 
[Ballard, Wolff et al. 2002]. 
 
IV. Histone Biotinylation 
 
Hisotnes and Chromatin 
Histones are small basic proteins (11-22 kDa) involved in the folding of the DNA 
into chromatin.  They are modified by the covalently binding of biotin to lysine residues 
by holocarboxylase synthetase [Wolffe 1998; Stanley, Griffin et al. 2001].  There are five 
major classes of histones in chromatin: H1, H2A, H2B, H3 and H4 [Wolffe 1998].  
Histones H2A, H2B, H3 and H4 form an octamer of core histones with one H3-H3-H4-
H4 tetramer and two H2A-H2B dimers while histone H1 is the linker histone bound to 
the DNA in between two nucleosomes (Fig. 6) [Kothapalli, Camporeale et al. 2005].  
Importantly, histones are positively charged proteins due to the presence of a large 
number of lysine and arginine residues (20-25% of the amino acids).  The electrostatic 
interaction between the negative charge of DNA and the positive charge of histones 
stabilizes the formation of the nucleosomal core particle [Wolffe 1998]. 
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Figure 6. Nucleosome structure.  Histone H1 and octamer. 
 
 
Covalent Histone Modifications 
Histones are target for reversible covalent modifications such as acetylation, 
methylation, phosporylation, poly (ADP-ribosylation) and biotinylation.  These 
modifications have distinct functions in gene expression, chromatin remodeling, 
transcriptional regulation, and DNA repair [Turner 2000; Moore and Krebs 2004; Narang, 
Dumas et al. 2004; Khan and Krishnamurthy 2005].  For example, acetylation of lysine 
residues has been associated with transcriptional activity of genes [Bannister, Schneider 
et al. 2002].  Methylation may be associated with transcriptional activation or repression.  
Phosphorylation and poly (ADP-ribosylation) are associated with signaling and DNA 
repair [Peters, Griffin et al. 2002]. 
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Histone Biotinylation 
In previous studies, 11 biotinylation sites in histones have been identified: K9, 
K13, K125, K127 and K129 in histone H2A [Chew, Camporeale et al. 2006]; K4, K9, 
K18 and perhaps K23 in histone H3 [Kobza, Sarath et al. 2008]; and K8 and K12 in 
histone H4 [Camporeale, Shubert et al. 2004] (Fig. 7 [Ho and Zempleni 2009]). 
 
                
                  
Figure 7. Modification marks in histones H2A, H3, and H4 ([Figure source: Ho and 
Zempleni 2009]).  Abbreviations: Ac, acetate; B, biotin; M, methyl; P, phosphate; U, 
ubiquitin [Jenuwein and Allis 2001; Fischle, Wang et al. 2003; Camporeale, Shubert et al. 
2004; Kobza, Camporeale et al. 2005; Chew, Camporeale et al. 2006; Chew, Raza et al. 
2006; Kouzarides and Berger 2007; Kobza, Sarath et al. 2008].  Marks labeled with “?” 
are based on preliminary observations and await confirmation [Camporeale, Shubert et al. 
2004; Chew, Raza et al. 2006]. 
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Biotinylation of histones plays an important role in the cellular response to DNA 
damage [Kothapalli, Sarath et al. 2005], cell proliferation [Stanley, Griffin et al. 2001], 
and mitotic condensation of chromatin [Kothapalli and Zempleni 2005]. In fact, 
H4K12bio has been associated with gene silencing [Camporeale, Oommen et al. 2007] 
and repression of transponsable elements [Chew, West et al. 2008]. 
 
The Role of HCS in Biotinylation of Histones 
The important role of HCS in biotinylation of histones has been confirmed in 
various studies [Leon-Del-Rio, Leclerc et al. 1995; Camporeale, Giordano et al. 2006].  
Camporeale et al. compared the ability of SMVT mutants and HCS-deficient Drosophila 
melanogaster to biotinylate histones.  The results demonstrated that HCS knockdown is 
associated with a decrease in biotinylation of histones due to the low biotin-ligase activity, 
rather than the low levels of biotin in the cells [Leon-Del-Rio, Leclerc et al. 1995].  
Importantly, Bao et al. recently reported that HCS interacts physically with histone H3 to 
mediate binding to chromatin and subsequent biotinylation of K9 and K18 in histone H3 
[Bao, Pestinger et al. 2011].  
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MATERIALS AND METHODS 
Candidate SNPs selection 
As of May 7, 2011, 2572 SNPs in HCS gene have been reported on “GeneCards” 
website (http://www.genecards.org/cgibin/carddisp.pl?gene=HLCS&snp=2572&rf=/ 
home/genecards/current/website/carddisp.pl#snp).  The SNPs in the coding region of 
HCS gene were detected out of these.  Candidate SNPs were then limited to those which 
cause amino acid changes.  Furthermore, candidate SNPs were limited to those which 
were suspected to cause HCS conformational changes, e.g., substitution of basic for 
hydrophobic amino acid, for further biochemical analysis. 
 
Recombinant HCS      
 A clone of full-length human HCS was provided by Yoichi Suzuki (Tohoku 
University, Sendai, Japan) [18].  EcoRI and XhoI restriction sites were inserted by PCR, 
using forward primer 5’-GTCCGAATTCGGGGAAGATAGACTCCACATGGATAAT 
G-3’ and reverse primer 5’-ATTTCTCGAGCCCGCCGTTTGGGGAG-3’.  The PCR 
product was digested with EcoRI and XhoI and cloned into vector pET41a(+) (Novagen, 
Madison, WI), fusing glutathione S-transferase (GST), S·tag, and a 6x his·tag to the N-
terminus of HCS; this construct also contains a 6x his·tag at the C-terminus of HCS.  The 
plasmid was named “HCS-pET41a(+)” and codes for a fusion protein of 114.6 kDa; its 
identity was verified by sequencing [Bao, Pestinger et al. 2011].  
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Site-directed mutagenesis 
 5 kinds of different SNPs in HCS gene were chosen for further analysis.  HCS-
pET41a(+) was digested with EcoRI and XhoI and subcloned into vector pBluescript II 
SK (+) (Stratagene; Wilmington, DE).  The plasmid was named “HCS- pBluescript II SK 
(+)”.  Each mutation was introduced to HCS-pBluescript II SK (+) using GeneTailor™ 
Site-Directed Mutagenesis System (Invitrogen; Carlsbad, CA).  Each plasmid was then 
digested with EcoRI and XhoI and subcloned into vector pET41a(+). 
 
Expression and purification of recombinant HCS                    
 ArcticExpress (DE3) Competent Cells (Agilent Technologies; Santa Clara, CA) 
transformed with HCS-pET41a(+) [Bao, Pestinger et al. 2011] were cultured in LB Broth 
Medium with 20 μg/ml of gentamycin and 50 μg/ml of kanamycin, and incubated 
overnight at 37°C.  Bacteria were allowed to grow until an OD600 of 0.5- 1.0 was 
reached.  Protein expression was induced adding Isopropyl-beta-D-thiogalactopyranosid 
(IPTG) at a final concentration of 1mM, and incubated at 12ºC for 24 hours.  Cells were 
centrifuged at 4ºC (3,000 g for 30 minutes) and precipitated cells were resuspended in 
PBS with protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO).  Samples were 
sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) three times for 10-second 
burst and alternated with 10-second resting periods on ice.  The lysate were centrifuged at 
10,000 g for 10 minutes at 4ºC.  HCS fusion protein were purified by GSTrap™ FF 
Columns (GE Healthcare; Piscataway, NJ) on ÄKTA™ protein purification system (GE 
Healthcare).  HCS in column fraction were identified by gel electrophoresis followed by 
23 
 
coomassie blue staining and western blot using an antibody to the C-terminus in human 
HCS.  
 
Expression and purification of recombinant p67 
 The polypeptide p67 is frequently used to confirm biological activity of HCS.  It 
is the C-terminal 67 amino acid biotin carboxyl carrier (BCC) domain of the propionyl-
CoA carboxylase (PCC) α subunit (Leu637-Glu703).  Rosetta™ 2(DE3) Competent Cells 
(EMD Chemicals; Gibbstown, NJ) transformed with p67- pET30 [Kobza, Sarath et al. 
2008] were cultured in LB Broth Medium with 15 μl of kanamacyn, and incubated 
overnight at 37°C.  Cells were allowed to grow until an OD600 of 0.5 - 0.6 was reached.  
p67 expression was induced by IPTG 1 mM final concentration and incubated for 16 
hours at 37ºC.  After incubation, samples were centrifugated at 3,000 g for 30 minutes 
and purified using His Trap FF Columns (GE Healthcare) on an ÄKTA™ protein 
purification system (GE Healthcare).  Because BirA ligase in Escherichia coli is known 
to biotinylate some of the recombinant p67, the biotinylated fraction of p67 was removed 
using avidin columns. 
 
Normalization of the HCS constructs 
 Purified proteins of wild-type HCS and its variants were mixed with NuPAGE® 
LDS Sample Buffer (4X) (Invitrogen), boiled at 95 ºC for 10 minutes, and loaded into 
NuPAGE® Novex 4-12% Bis-Tris Gel (Invitrogen).  Relative concentrations of each 
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recombinant HCS (rHCS) construct were normalized by staining with coomassie blue 
and by western blot using an antibody to the C-terminus in human HCS. 
 
HCS catalytic activity assay using p67 as substrate 
 Bioactivity of the purified HCS (50 nM) was measured using 50 μl of a mix 
containing 75 mM Tris- Acetate (pH 7.5), 7.5 mM ATP, 0.3 mM dithiothreitol (DTT), 45 
mM MgCl2, 45 μM p67 and graded concentration of biotin (0, 1, 3, 6, 12 and 24 μM).  
The mix was incubated at 37 ºC for 3 hours.  50 μl of tricine loading buffer was added to 
the mix.  The mix (100 μl) was boiled at 95 ºC for 10 minutes.  15 μl of the sample was 
loaded and run on a 16% tricine gel.  The gel was transferred onto the PVDF membrane.  
The membrane was dipped in PBS to remove traces of transfer buffer, incubated with 
Odyssey blocking buffer (Licor; Lincoln, NE) at room temperature for 1 hour, and 
washed with 0.1% T-PBS (PBS containing 0.1% Tween 20) at room temperature 3 times 
- 5 minutes each - with gentle rotation.  The membrane was then transferred to a black 
tray containing 2.5 µL of the stock solution of IRDye 800CW Streptavidin (Licor; 2.4 
moles of IRDye 800 CW/1 mole of streptavidin) in 20 mL of 0.1% TPBS and incubated 
for 1 hour at room temperature.  The membrane was washed with 0.1% TPBS containing 
5 M NaCl at room temperature 4 times - 5 minutes each - with gentle rotation.  The 
membrane was scanned to detect the probed p67-bound biotin by measuring infrared 
absorbance of IRDye 800CW Streptavidin at 800 nm (channel 800CW) in the Odyssey 
imaging system.  Non-linear regression analysis was used to calculate Km and Vmax of 
25 
 
HCS for biotin using the software “GraphPad Prism 5.00” (GraphPad Software; La Jolla, 
CA). 
 
Statistical Analysis 
Homogeneous variances were identified by using Bartlett’s test.  Significance of 
differences was tested by one-way ANOVA.  Fisher’s Protected Least Significant 
Difference procedure was used for posthoc testing.  StatView 5.0.1 (SAS Institute; Cary, 
NC) was used to perform all calculations.  Differences were considered significant if P < 
0.05.  Data were expressed as mean ± SD. 
 
 
RESULTS 
Bioinformatics 
It turned out that there are 14 HCS variants overall in the coding region of HCS in 
GeneCards database.  6 variants of them do not cause amino acid changes (group 1).  4 
variants of them cause amino acid changes, but the side chains have exactly the same 
characteristics before and after the substitutions (group 2): the substitution of aspartate 
for glutamate (both have hydrophilic and negatively charged R groups), the substitution 
of histidine for arginine (both have hydrophilic and positively charged R groups) and the 
substitution of leucine or isoleucine for valine (SNP ID: rs61731502; both have 
hydrophobic R groups).  The rest 4 variants cause amino acid substitutions by which the 
characteristics of the side chains also change (group 3). The variant rs61732502 
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substitutes phenylalanine (hydrophobic and aromatic R groups) for valine (hydrophobic 
and aliphatic R groups), the variant rs28934602 substitutes arginine (hydrophilic and 
positively charged R groups) for leucine (hydrophobic and neutral R groups), the variant 
rs75867009 substitutes arginine for glycine (hydrophobic and positively charged R 
groups) and the variant rs79373682 substitutes arginine for glutamine (hydrophobic and 
positively charged R groups). 
The 5 variants below – one from group 2 and all four variants from group 3 - were 
chosen for further catalytic analysis (Table 1). 
 
Table 1. HCS variants 
  
SNP ID 
nucleotide 
substitution 
amino acid 
substitution 
amino acid side chains' characteristics 
HCS 
domain 
rs61732502 G286T V96F 
 Both are hydrophobic. 
 aliphatic → aromatic 
N-terminal 
rs61732502 G286C V96L                Both are hydrophobic. N-terminal 
rs28934602 T647G L216R 
hydrophobic and neutral →  hydrophilic and 
basic (positively charged) 
N-terminal 
rs75867009 G1528A G510R 
 neutral → basic (positively charged) 
 Both are hydrophilic. 
 Arginine is much bulkier than 
Glycine. 
central 
rs79373682 A2096G Q699R 
 neutral → basic (positively charged) 
 Both are hydrophilic. 
C-terminal 
 
 
Recombinant HCS and p67 
After recombinant proteins of wild-type HCS and the variants shown above were 
produced, relative concentrations of each recombinant HCS (rHCS) construct were 
normalized by staining with coomassie blue (Fig. 8 (a)) and by western blot using an 
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antibody to the C-terminus in human HCS (Fig. 8 (b)).  Recombinant p67 is biotinylated 
by BirA in E. coli and therefore requires affinity purification before use.  When 
recombinant p67 was purified by using avidin columns, the vast majority of biotinylated  
p67 was removed.  For all assays described below, biotin-depleted p67 was used. 
 
                                     
          
                                     
                                  
Figure 8. Normalization of rHLCS concentrations for enzyme kinetics studies.  
Wild-type HLCS (WT) and variants were stained with coomassie blue (panel a) and 
probed with anti-HLCS (panel b).  1: WT, 2: V96F, 3: V96L, 4: L216R, 5: G510R, 6: 
Q699R. 
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Dose-response studies in HCS catalytic activity assay using p67 as substrate 
A titration of wild-type rHCS was conducted with overabundant amount of p67 
(45 µM) and biotin (100 µM) to determine a concentration where enzyme concentration 
is proportional to the amount of substrate biotinylation when substrate and coenzyme 
availability are not limiting factors in this HCS catalytic assay.  The amount of 
biotinylated p67 in this assay increased linearly up to a concentration of rHCS of 60 nM, 
and leveled off thereafter.  Subsequent experiments were conducted using 50 nM HCS to 
ensure assay linearity. 
Then p67 was titrated with an overabundant amount of biotin (100 µM) to 
determine a concentration where substrate availability is no longer a limiting factor in 
this assay.  A linear dose-response was obtained for up to 20 μM p67, while p67 was no 
longer rate limiting beyond that concentration.  For subsequent experiments, p67 was 
used at a concentration of 45 μM. 
 
Kinetics analysis of p67 biotinylation by wild-type rHCS and its variants 
We determined the kinetic properties of the wild-type and five rHCS variants 
using p67 as substrate.  Table 2, Fig. 9 and Fig. 10 show Km values for biotin and Vmax 
values of the rHCS constructs.  Note that the activity of L216R was too low to allow for 
meaningful analysis of Km.  All these Vmax and Km values were homogeneous.  Fig. 11 
(a) – (e) are the graphs of initial velocity depending on biotin concentration.  Three 
variants, V96F, V96L and L216R, are within the N-terminal domain (aa1-446).  The 
variant Gly510Arg is within the central domain (aa471-575).  And the variant Q699R is 
within the C-terminal domain (aa669-718). 
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Three variants, V96F, L216R and G510R, had significantly different Vmax values 
compared with that of the wild type.  The Vmax values of V96F and G510R variants were 
decreased to a slight extent: 78% and 73%, respectively (percentage of the wild-type 
value), and the Vmax value of L216R variant was markedly decreased: 6%. 
Only the Q699R variant had significantly different Km value compared with that 
of the wild type.  The Km values of this mutant enzyme for biotin were higher than that of 
the wild type by 57%. 
 
 
 
Table 2. Vmax and Km values of wild-type rHCS and its variants 
  WT V96F V96L L216R G510R Q699R 
Vmax (pmol biotin/(h*pmol HCS) ) 3.9±0.3 3.0±0.5 4.1±0.4 0.2±0.04 2.8±0.5 3.9±0.6 
Vmax (% wild type) 100 78 106 6 73 101 
       
     Km (µM) 4.0±1.0 4.0±1.9 5.1±1.4  n.d. * 3.4±1.9 6.3±2.6 
Km (fold over wild type) 1 1 1.27  n.d. * 0.84 1.57 
* n.d.=not detectable.  The activity of L216R was too low to allow for meaningful analysis of Km. 
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Figure 9. Vmax values of the wild-type rHCS and its variants.  rHCS was incubated 
with p67, biotin and cofactors for 3 hours; enzyme activity was measured by infrared 
spectroscopy.  Bars without a common letter are significantly different (n=3, P<0.05).  
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Figure 10. Km values of the wild-type rHCS and its variants.  rHCS was incubated 
with p67, biotin and cofactors for 3 hours; enzyme activity was measured by infrared 
spectroscopy.  Note that the activity of L216R was too low to allow for meaningful 
analysis of Km.  Bars without a common letter are significantly different (n=3, P<0.05). 
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Fig 11 (a)-(e). Non-linear regression analysis of HLCS variants V96F (panel a), 
V96L (b), L216R (c), G510R (d), and Q699R (e) compared with wild-type HLCS.   
Data points were fitted by using the Michaelis-Menten equation (N=3 independent 
analyses for each HCS variant). Abbreviations: WT = wild type. 
 
 
SNPs that affect the catalytic activity of HCS 
The variant V96F had 78% Vmax and 100% Km of that of the wild type, suggesting 
that this variant’s affinity for biotin was the same level as wild type, and the activity of 
this enzyme was compromised by 22% but not restored with higher concentrations of 
biotin. 
The variant V96L had 106% Vmax and 127% Km of that of the wild type, 
suggesting that the affinity for biotin and the activity of this variant were the same level 
as wild type statistically. 
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The variant L216R had as low as 6% Vmax of that of the wild type (Km value was 
not available), suggesting that the activity of this enzyme was compromised by 94% but 
not restored with higher concentrations of biotin. 
The variant G510R had 73% Vmax and 84% Km of that of the wild type, 
suggesting that this variant’s affinity for biotin was the same level as wild type 
statistically, and the activity of this enzyme was compromised by 27% but not restored 
with higher concentrations of biotin. 
The variant Q699R had 101% Vmax and 157% Km of that of the wild type, 
suggesting that this variant’s affinity for biotin was lower by 57% than wild type, and the 
activity of this enzyme was the same level as wild-type enzyme because it was restored 
with higher concentrations of biotin. 
 
The concentration of biotin needed to achieve normal substrate biotinylation by 
HCS variants compared with wild-type HCS 
Of the 5 variants studied here, V96L variant showed the same affinity for biotin 
and the same activity as wild-type enzyme.  The activity of the variants V96F, L216R 
and G510R was compromised but not restored with higher concentrations of biotin. 
In contrast, the affinity of variant Q699R for biotin was significantly lower than 
that of wild type HCS (Km: 1.57 times that of wild type) and its Vmax could be restored to 
that of wild-type HCS by biotin supplementation (Fig. 11-(e)). 
Our knowledge of the intracellular concentrations of biotin in mammalian tissues 
is rather limited.  Evidence suggests that the concentrations of biotin in liver and kidney 
is about 3.3 µmol/kg and 4.5 µmol/kg, respectively, in pigs fed a normal diet containing 
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200 µg biotin/kg [Kopinski, 1989].  Likewise, the concentration of biotin is about 
500―900 fmol per cell in human embryonic palatal mesenchymal cells in culture 
[Takechi, 2008], which translates into a concentration of about 6.8 µmol/L assuming a 
cellular volume of 0.3 nL [Nibbering, 1990]. The tissue concentration of free biotin might 
be lower than that of protein-bound biotin [Rathman, 2002], but this might be offset by 
local accumulation of free biotin in HLCS-rich microdomains.  Notwithstanding the 
uncertainties with regard to the true concentrations of biotin in human tissues and cellular 
compartments, we are reasonably confident that the Km values reported for HCS in this 
study are similar to the concentrations of biotin in human tissues.  If so, biotin 
supplementation might benefit individuals homozygous for the HLCS variant Q699R. 
 
 
DISCUSSION 
 
The two objectives of this study were (1) to identify HCS SNPs that affect the 
catalytic activity of HCS and (2) to determine if higher concentration of biotin could 
restore normal substrate biotinylation by HCS variants compared with wild-type HCS. 
There have been multiple reported mutations in the HCS gene that give rise to 
MCD (reviewed in Bailey et al. 2008 [Pendini, Bailey et al. 2008]; summarized in Table 
3).  The severity of disease varies greatly with the genotype of each individual.  Broadly, 
the mutations can be classified into two groups.  Firstly the Km mutants are amino acid 
substitutions that result in an enzyme with decreased affinity for biotin.  Patients bearing 
these mutant HCS respond well to oral administration of pharmacological doses of biotin.  
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Secondly, the Vmax mutants are substitutions where the activity of the enzyme is 
compromised but not restored with higher concentrations of biotin. 
According to these mutant theories, V96F, L216R and G510R variants are Vmax 
mutants, and Q699R variant is a Km mutant for the variants studied in this thesis.  This 
observation agrees with the report by Sakamoto et al. [Sakamoto, Suzuki et al. 1999] that 
L216R is a Vmax mutant, and with the report that most of the Km mutants lie in the C-
terminal catalytic portion of the enzyme [Pendini, Bailey et al. 2008].  To date there are 
no reports of an X-ray structure for human HCS, but recent studies reporting new 
structures of BPL from bacteria E. coli has provided powerful insights into the HCS 
structure. 
 
Table 3. Biochemical characterisation of HCS missense mutations. [Table source: 
Bailey et al. 2008] 
Mutation Activity (% wildtype) Km Biotin (fold over wildtype) 
Wildtype 100 1 
E42D 120 N.D. 
R183P 1.7 0.6 
L216R 0.3 1.4 
L237P 1.2-4.3 0.4–1.2 
V333E 2–10 1.5 
R360S 22 N.D. 
V363D 3.7 1.1 
Y456C 0.2 N.D. 
T462I <10 N.D. 
L470S 4.3 N.D. 
R508W 34.5 23 
V547G 3.4 N.D. 
V550M 16.6 6.5 
D571N 0.1 N.D. 
G581S <10 44.3 
D634Y 12 N.D. 
Amino acid substitutions in the catalytic region (residues 422–726) induce a 3–44-fold elevated 
Km  for biotin compared to wildtype HCS. N.D: Not determined. 
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Unlike mutations in the HCS gene, there have been no reports which focused on 
SNPs in the HCS gene to date.  For a variation to be considered a SNP, it must occur in at 
least 1% of the population.  SNPs, which make up about 90% of all human genetic 
variation, occur every 100 to 300 bases along the 3-billion-base human genome.  Many 
SNPs have no effect on cell function, but others could predispose people to disease or 
influence their response to a drug, etc.  This is the first comprehensive study of the 
catalytic activity of HCS SNPs. 
Of the 5 substitutions studied in this thesis, L216R has already been reported in 
the UniProt database (P50747).  This allele was first reported as a mutation in the human 
HCS gene, and has subsequently appeared to occur at a high frequency in the Samoan 
and Cook Island populations  [Morrone, Malvagia et al. 2002], which is probably the 
reason why this variant was determined as a SNP.  As our data in this thesis shows, this 
allele results in markedly reduced enzyme activity.  According to the report by Morrone 
et al., five of the seven homozygous patients with this variant died between age 3 days to 
3 years.  All patients presented within 24 hours of birth with severe acidosis.  The two 
babies that did not receive biotin treatment died within seven days.  Despite biotin 
therapy, three of the patients continued to show severe dermatological symptoms and 
recurrent septicaemia followed by metabolic decompensation.  All died during one of 
these episodes [Morrone, Malvagia et al. 2002].  In contrast, a patient with this variant in 
the heterozygous form (L216R /V363D) showed good clinical response to biotin therapy 
(10–40 mg/day) [Dupuis, Campeau et al. 1999].  Biotin responsiveness was attributed to 
the presence of the biotin-responsive allele V363D.  Patients homozygous for the L216R 
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variant have since been reported and, their response to biotin therapy has varied for some 
reason [Wilson, Myer et al. 2005].  Interestingly, a recent study demonstrated that this 
variant induced increased protein turnover thereby providing a partial explanation for the 
poor response to biotin therapy [Bailey, Ivanov et al. 2008].  Further crystallographic 
studies on the HCS structure will be required to fully understand how mutations distal 
from the active site of HCS have an effect on function. 
Blast search against PDB databank returned prokaryotic biotin ligase (BirA) 
structures alignment to the central and C-terminal domains of the human HCS (alignment 
from around residues 460 to 710 aa), with approximately 31% sequence identity.  A 3D 
modeling would give detailed information about the changed molecular interactions due 
to the substitution. However, modeling is only possible for the central and C-terminal 
domains (i.e. for G510R and Q699R), for which structural information is available while 
no human or eukaryotic biotin ligase structure is available to date. 
HCS substitutions G510R and Q699R are located at the equivalent sites in the 
bacterial structures, indicating that substitution sites 510 and 699 are not in the biotin 
binding site and are located in the solvent exposed exterior of the protein (Fig. 12 and Fig. 
13).  In the central domain of human HCS, the R508-S515 loop corresponds to one of the 
biotin-binding site (R118-S125) in BirA [Hassan, Moriyama et al. 2009].  However, 
substitution G510R does not yield any specific hydrogen bond interactions with the co-
factor.  In contrast, the mutations R508W and N511K have been reported to cause severe 
damage to the catalytic activity of HCS [Pendini, Bailey et al. 2008] (Fig. 12) because 
these sites are critical residues in the loop covering the ligand-binding site and R508 co-
ordinates to the backbone carbonyl N712 to form a salt bridge, removing this would 
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result in a more flexible loop.  The residue 510 in HCS is also close to the putative 
carboxylase binding site, but this can not be reliably predicted from the E.coli BirA -
BCCP structure due to very limited structural information and moreover, the human 
carboxylases are structurally not very similar to BCCP.  Q699R occurs in a turn at the 
end of a β-strand and would not drastically change the packing of the molecule as it is in 
a solvent exposed loop.  These observations suggest that these two variants do not 
majorly change the protein structure to affect its function.  Thus probably the variants 
G510R and Q699R are presumed to be not critical for the protein folding or function.  
This inference agree with our kinetics data in this thesis: Vmax values of variants G510R 
and Q699R were 73 and 101% of that of the wild type, and Km values were 0.84 and 1.57 
times that of the wild type, respectively.  These kinetics data suggest that these two 
variants do not majorly change the catalytic activity of HCS, whereas Vmax value of 
variant L216R was only 6% of the Vmax in wild-type HCS and this variant causes 
multiple carboxylase deficiency (MCD) as mentioned above. 
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Fig. 12. R508W, N511K and other mutations in the central and C-terminal domains 
of HCS [Figure source: Pendini, Bailey et al. 2008]. Residues that are mutated in 
multiple carboxylase deficiency (MCD) are highlighted (in red) on the HCS model with 
biotinyl-5′-AMP shown in the active site (in stick and ball representation). It can be seen 
from this model that these mutations cluster around the biotin and ATP binding sites. 
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Fig. 13. Substitution sites 510 and 699 in the central and C-terminal domains of 
HCS. The substituted residues (510R and 699R) are highlighted in purple, while the wild 
type residues are highlighted in blue. The biotinyl 5’-AMP bound at the active site is 
highlighted in cyan. Substitution G510R occurs in one of the biotin-binding site (R508-
S515 loop). Q699R occurs in a turn at the end of a β-strand. Either substitution site (510 
and 699) is not involved in the biotin binding site and is located in the solvent exposed 
exterior of the protein. 
 
In summary, Vmax of variants L216R, V96F and G510R variant were 6%, 78% 
and 73%, respectively, of the Vmax in wild-type HCS.  The Km values of the variants 
V96F and G510R were not significantly different from wild-type HCS.  The activity of 
L216R was too low to allow for meaningful analysis of Km.  In contrast, the affinity of 
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variant Q699R for biotin was significantly lower than that of wild type HCS (Km: 1.57 
times that of wild type) and its Vmax could be restored to that of wild-type HCS by biotin 
supplementation.   This is the first biochemical characterization of catalytic activities of 
HCS variants.  Also, this is the first report to show that HCS activity can be restored to 
normal by biotin supplementation. 
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